Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
CALU	rs339097	G	warfarin	dosage	no	Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that "SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model."	Allele G is not associated with dose of warfarin in people with heart valve replacement as compared to allele A.	25126975	1184757033
CALU	rs339097	G	warfarin	dosage	yes		Allele G is associated with increased dose of warfarin.	20200517	637879876
CALU	rs2290228	A	warfarin	dosage	no	in Korean patients with mechanical cardiac valves.	Allele A is not associated with decreased dose of warfarin as compared to allele G.	22549502	1184510047
CALU	rs339097	AG + GG	warfarin	dosage	no	A p value of 0.04 was given for dose- genotype association, but the authors stated that this association did not reach significanc in multiple regression testing (p = 0.066), and that was likely due to insufficient power.Variant allele carriers required 14.1 mg/week more warfarin than AA.	Genotypes AG + GG are associated with increased dose of warfarin as compared to genotype AA.	21228733	827864550
CALU	rs339097	G	warfarin	dosage	yes		Allele G is associated with increased dose of warfarin.	20200517	608431797
CALU	rs339097	G	warfarin	dosage	yes		Allele G is associated with increased dose of warfarin.	20200517	637879873
CALU	rs1043550	A	warfarin	dosage	no	No significant differences in therapeutic warfarin dose (mg/wk) or error in predicted dose were seen between any of the genotypes (AA, AG, GG). Note that the study cohort differed from Hardy-Weinberg equilibrium.	Allele A is not associated with dose of warfarin as compared to allele G.	23656803	1184165651
CALU	rs2290228	A	warfarin	dosage	no	Neither the addition of race, number of concurrent medications nor the number of concurrent medications interacting with warfarin enhanced algorithm performance. Similarly, consideration of CYP4F2, CALU or GGCX variant genotypes did not improve algorithms.	Allele A is not associated with dose of warfarin as compared to allele G.	20128861	1184472408
CALU	rs1043550	AA	phenprocoumon	"dosage","metabolism/PK"	yes	Daily dose of phenprocoumon is not significantly associated with this SNP. Daily dose is negatively correlated with age. This study published an algorithm for daily dose that includes height, although height was not significant in univariate analysis. This SNP is also not significantly associated with phenprocoumon concentration.	Genotype AA is not associated with increased dose of phenprocoumon as compared to genotypes AG + GG.	21110013	982046676
CALU	rs1043550	AA	acenocoumarol	dosage	no	The AA patients needed lower doses than g carriers (15.8 ± 5.9 mg/week vs. 18.1 ± 5.9 mg/week, respectively), although these differences did not reach statistical significance. Carriers of this variant and VKORC1 rs9934438 variant (27% of the sample) achieved the highest INR [2.26 (1.70-3.32)] and required the lowest dose (14.1 +/- 5.1 mg week(-1)).	Genotype AA is associated with decreased dose of acenocoumarol as compared to genotypes AG + GG.	17596133	1444707135
CALU	rs2290228	G	warfarin	dosage	no	Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that "SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model."	Allele G is not associated with dose of warfarin in people with heart valve replacement as compared to allele A.	25126975	1184757003
CALU	rs1043550	G	acenocoumarol	dosage	yes	Normalized maintenance dose (NMD): mean maintenance dose/INR at equilibrium). A final multivariate regression model explained 48.1% of the global inter-individual variability in dose requirement. The authors created a clinical algorithm (CA) using patient’s clinical and demographic variables used in the PA.	Allele G is associated with increased dose of acenocoumarol in people with Atrial Fibrillation as compared to allele A.	29479633	1449188291
CALU	rs1043550	G	warfarin	dosage	no		Allele G is not associated with dose of warfarin as compared to allele A.	28049362	1449246724